Investors & Media

Stock Info
NASDAQBCLI
Company Information

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Alzheimer’s Disease (AD).

Investor Presentation – October 2024

Recent News
Oct 7, 2024
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced its participation in the 2024 Maxim Healthcare...

Sep 24, 2024
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the acceptance of two abstracts featuring NurOwn®...

Aug 14, 2024
BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

- Company reached alignment with the U.S. FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its planned Phase 3b clinical trial for NurOwn® in ALS - SPA in place for Phase 3b...

View All

Events
Investor Presentation - October 2024
Tuesday, October 1, 2024

View All

Email Alerts
Email Alerts
Investor Contact
Investor Contact
Investor FAQs
Investor FAQs
RSS Feeds
RSS Feeds
Investors